On Tuesday, Enliven Therapeutics Inc (NASDAQ: ELVN) opened lower -5.02% from the last session, before settling in for the closing price of $20.52. Price fluctuations for ELVN have ranged from $13.30 to $25.67 over the past 52 weeks.
During the last 5-year period, the sales growth of Healthcare Sector giant was 19.02%. Company’s average yearly earnings per share was noted 8.68% at the time writing. With a float of $43.25 million, this company’s outstanding shares have now reached $59.26 million.
Enliven Therapeutics Inc (ELVN) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Enliven Therapeutics Inc is 27.12%, while institutional ownership is 77.97%. The most recent insider transaction that took place on Dec 08 ’25, was worth 145,320. Before that another transaction happened on Nov 19 ’25, when Company’s CHIEF SCIENTIFIC OFFICER sold 12,500 for $22.33, making the entire transaction worth $279,155. This insider now owns 902,688 shares in total.
Enliven Therapeutics Inc (ELVN) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.46 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.52) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 8.68% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.76% during the next five years compared to 19.02% growth over the previous five years of trading.
Enliven Therapeutics Inc (NASDAQ: ELVN) Trading Performance Indicators
Check out the current performance indicators for Enliven Therapeutics Inc (ELVN). In the past quarter, the stock posted a quick ratio of 32.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.85, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -1.92 in one year’s time.
Technical Analysis of Enliven Therapeutics Inc (ELVN)
Looking closely at Enliven Therapeutics Inc (NASDAQ: ELVN), its last 5-days average volume was 0.64 million, which is a jump from its year-to-date volume of 0.43 million. As of the previous 9 days, the stock’s Stochastic %D was 48.75%.
During the past 100 days, Enliven Therapeutics Inc’s (ELVN) raw stochastic average was set at 34.31%, which indicates a significant decrease from 36.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.36 in the past 14 days, which was higher than the 1.22 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.83, while its 200-day Moving Average is $20.02. However, in the short run, Enliven Therapeutics Inc’s stock first resistance to watch stands at $20.83. Second resistance stands at $22.17. The third major resistance level sits at $23.93. If the price goes on to break the first support level at $17.73, it is likely to go to the next support level at $15.97. Should the price break the second support level, the third support level stands at $14.63.
Enliven Therapeutics Inc (NASDAQ: ELVN) Key Stats
There are currently 59,347K shares outstanding in the company with a market cap of 1.16 billion. Presently, the company’s annual sales total 0 K according to its annual income of -89,020 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -20,150 K.
